Tag Archives: chemo-immunotherapy
Weighing the clinical significance of new clinical trial results with immunotherapy in stage III and IV NSCLC
KEYNOTE-407: Practice-Changing Positive Trial for Advanced Squamous NSCLC (BMIC-039)
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting. (9:32)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (<1%) Tumor PD-L1 Expression (BMIC-033)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (<1%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset. (6:31)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset. (6:15)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients. (7:57)
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advanced non-squamous NSCLC with any PD-L1 expression. (13:05)
Is There Still a Value in Testing for PD-L1 Expression in Advanced NSCLC Today? (BMIC-005)
Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 status in patients with advanced non-squamous NSCLC. (2:40)